Rheumatoid Arthritis

Percentage of Rheumatoid Arthritis Patients Taking Disease Modifying Antirheumatic Drug Therapy (2015-2019)

Percentage of Rheumatoid Arthritis Patients Taking Disease-Modifying Antirheumatic Drug Therapy (N=10489)

2016-2020

DMARDs include both biologic and non-biologic agents

American College of Rheumatology guidelines recommend that rheumatoid arthritis patients be treated with disease-modifying antirheumatic drug (DMARD) therapy. More than 10489 unique rheumatoid arthritis patients were seen in the Department of Rheumatology between 2016-2020. More than 93.5% of rheumatoid arthritis patients who were seen in the Department of Rheumatology at least 2 times during the years 2016-2020 were treated with DMARD therapy in any given year. For the small percentage of patients not on DMARDs, reasons included disease remission, refusal of treatment, and contraindications to DMARD therapy. In any given year, between 93.5% and 94% of patients were on a DMARD.